Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells

Spinal glial activation contributes to the development and maintenance of chronic pain states, including neuropathic pain of diverse etiologies. Cannabinoid compounds have shown antinociceptive properties in a variety of neuropathic pain models and are emerging as a promising class of drugs to treat...

ver descrição completa

Detalhes bibliográficos
Autores: Burgos, Elisa, Gómez-Nicola, Diego, Pascual, David, Isabel Martín, María, Nieto-Sampedro, Manuel, Goicoechea, Carlos
Formato: artículo
Fecha de publicación:2012
País:España
Recursos:Universidad Rey Juan Carlos
Repositorio:BURJC-Digital. Repositorio Institucional de la Universidad Rey Juan Carlos
OAI Identifier:oai:burjcdigital.urjc.es:10115/12383
Acesso em linha:http://hdl.handle.net/10115/12383
Access Level:acceso abierto
Palavra-chave:Farmacia
Paclitaxel
Peripheral neuropathy
Cannabinoid
Hyperalgesia
Cytokine
Rat
3207.11 Neuropatología
id ES_466d5c08e1c8a806b6a846f4d528cacc
oai_identifier_str oai:burjcdigital.urjc.es:10115/12383
network_acronym_str ES
network_name_str España
repository_id_str
spelling Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cellsBurgos, ElisaGómez-Nicola, DiegoPascual, DavidIsabel Martín, MaríaNieto-Sampedro, ManuelGoicoechea, CarlosFarmaciaPaclitaxelPeripheral neuropathyCannabinoidHyperalgesiaCytokineRat3207.11 NeuropatologíaSpinal glial activation contributes to the development and maintenance of chronic pain states, including neuropathic pain of diverse etiologies. Cannabinoid compounds have shown antinociceptive properties in a variety of neuropathic pain models and are emerging as a promising class of drugs to treat neuropathic pain. Thus, the effects of repeated treatment with WIN 55,212-2, a synthetic cannabinoid agonist, were examined throughout the development of paclitaxel-induced peripheral neuropathy. Painful neuropathy was induced in male Wistar rats by intraperitoneal (i.p.) administration of paclitaxel (1 mg/kg) on four alternate days. Paclitaxel-treated animals received WIN 55,212-2 (1 mg/kg, i.p.) or minocycline (15 mg/kg, i.p.), a microglial inhibitor, daily for 14 days, simultaneous with the antineoplastic. The development of hypersensitive behaviors was assessed on days 1, 7, 14, 21 and 28 following the initial administration of drugs. Both the activation of glial cells (microglia and astrocytes) at day 29 and the time course of proinflammatory cytokine release within the spinal cord were also determined. Similar to minocycline, repeated administration of WIN 55,212-2 prevented the development of thermal hyperalgesia and mechanical allodynia in paclitaxeltreated rats. WIN 55,212-2 treatment also prevented spinal microglial and astrocytic activation evoked by paclitaxel at day 29 and attenuated the early production of spinal proinflammatory cytokines (interleukin (IL)-1ß, IL-6 and tumor necrosis factor (TNF)-¿). Our results confirm changes in the reactivity of glial cells during the development of peripheral neuropathy induced by paclitaxel and support a preventive effect of WIN 55,212-2, probably via glial cells reactivity inactivation, on the development of this neuropathy.Farmacología, Nutrición y BromatologíaElsevier201420142012info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10115/12383reponame:BURJC-Digital. Repositorio Institucional de la Universidad Rey Juan Carlosinstname:Universidad Rey Juan CarlosInglésS2010/BMD-2308info:eu-repo/semantics/openAccessoai:burjcdigital.urjc.es:10115/123832026-06-24T12:48:17Z
dc.title.none.fl_str_mv Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells
title Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells
spellingShingle Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells
Burgos, Elisa
Farmacia
Paclitaxel
Peripheral neuropathy
Cannabinoid
Hyperalgesia
Cytokine
Rat
3207.11 Neuropatología
title_short Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells
title_full Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells
title_fullStr Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells
title_full_unstemmed Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells
title_sort Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells
dc.creator.none.fl_str_mv Burgos, Elisa
Gómez-Nicola, Diego
Pascual, David
Isabel Martín, María
Nieto-Sampedro, Manuel
Goicoechea, Carlos
author Burgos, Elisa
author_facet Burgos, Elisa
Gómez-Nicola, Diego
Pascual, David
Isabel Martín, María
Nieto-Sampedro, Manuel
Goicoechea, Carlos
author_role author
author2 Gómez-Nicola, Diego
Pascual, David
Isabel Martín, María
Nieto-Sampedro, Manuel
Goicoechea, Carlos
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Farmacia
Paclitaxel
Peripheral neuropathy
Cannabinoid
Hyperalgesia
Cytokine
Rat
3207.11 Neuropatología
topic Farmacia
Paclitaxel
Peripheral neuropathy
Cannabinoid
Hyperalgesia
Cytokine
Rat
3207.11 Neuropatología
description Spinal glial activation contributes to the development and maintenance of chronic pain states, including neuropathic pain of diverse etiologies. Cannabinoid compounds have shown antinociceptive properties in a variety of neuropathic pain models and are emerging as a promising class of drugs to treat neuropathic pain. Thus, the effects of repeated treatment with WIN 55,212-2, a synthetic cannabinoid agonist, were examined throughout the development of paclitaxel-induced peripheral neuropathy. Painful neuropathy was induced in male Wistar rats by intraperitoneal (i.p.) administration of paclitaxel (1 mg/kg) on four alternate days. Paclitaxel-treated animals received WIN 55,212-2 (1 mg/kg, i.p.) or minocycline (15 mg/kg, i.p.), a microglial inhibitor, daily for 14 days, simultaneous with the antineoplastic. The development of hypersensitive behaviors was assessed on days 1, 7, 14, 21 and 28 following the initial administration of drugs. Both the activation of glial cells (microglia and astrocytes) at day 29 and the time course of proinflammatory cytokine release within the spinal cord were also determined. Similar to minocycline, repeated administration of WIN 55,212-2 prevented the development of thermal hyperalgesia and mechanical allodynia in paclitaxeltreated rats. WIN 55,212-2 treatment also prevented spinal microglial and astrocytic activation evoked by paclitaxel at day 29 and attenuated the early production of spinal proinflammatory cytokines (interleukin (IL)-1ß, IL-6 and tumor necrosis factor (TNF)-¿). Our results confirm changes in the reactivity of glial cells during the development of peripheral neuropathy induced by paclitaxel and support a preventive effect of WIN 55,212-2, probably via glial cells reactivity inactivation, on the development of this neuropathy.
publishDate 2012
dc.date.none.fl_str_mv 2012
2014
2014
dc.type.none.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/10115/12383
url http://hdl.handle.net/10115/12383
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv S2010/BMD-2308
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:BURJC-Digital. Repositorio Institucional de la Universidad Rey Juan Carlos
instname:Universidad Rey Juan Carlos
instname_str Universidad Rey Juan Carlos
reponame_str BURJC-Digital. Repositorio Institucional de la Universidad Rey Juan Carlos
collection BURJC-Digital. Repositorio Institucional de la Universidad Rey Juan Carlos
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407227642642432
score 15,198674

Registos relacionados